Liposomes as cytokine-supplement in tumor cell-based vaccines.
Subcutaneous vaccination of C57bl/6 mice with irradiated B16 melanoma cells supplemented with liposomal interleukin-2 (IL2) or murine interferon-gamma (mIFNgamma), resulted in systemic protection in 50% of the animals, against a subsequent tumor cell challenge in a dose dependent manner. The protective efficacy was comparable to the efficacy of cytokine gene-modified cells as tumor vaccine, whereas irradiated B16 cells supplemented with soluble cytokine did not result in protective responses. In vivo evidence was obtained that the beneficial effects mediated by liposome incorporation of the cytokine are the result of a depot function of the liposomal cytokine supplement at the vaccination site. In can be concluded that liposomal delivery of cytokines offers an attractive alternative to cytokine-gene transfection of tumor cells for therapeutic vaccination protocols.
van Slooten
M L
ML
Department of Pharmaceutics, Utrecht University, PO Box 80.082, 3508 TB, Utrecht, The Netherlands. m.l.vanslooten@pharm.uu.nl
Kircheis
R
R
Koppenhagen
F J
FJ
Wagner
E
E
Storm
G
G
D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology*; D007371:Interferon-gamma / Q000008:administration & dosage* / Q000235:genetics; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000235:genetics; D008081:Liposomes / Q000008:administration & dosage*; D008546:Melanoma, Experimental / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D014162:Transfection; D014611:Vaccination
D019496:Cancer Vaccines; D007376:Interleukin-2; D008081:Liposomes; D007371:Interferon-gamma